KR20230030573A - 항-bet v1 항체를 사용하여 알러지를 치료하는 방법 - Google Patents

항-bet v1 항체를 사용하여 알러지를 치료하는 방법 Download PDF

Info

Publication number
KR20230030573A
KR20230030573A KR1020227043651A KR20227043651A KR20230030573A KR 20230030573 A KR20230030573 A KR 20230030573A KR 1020227043651 A KR1020227043651 A KR 1020227043651A KR 20227043651 A KR20227043651 A KR 20227043651A KR 20230030573 A KR20230030573 A KR 20230030573A
Authority
KR
South Korea
Prior art keywords
bet
antibody
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227043651A
Other languages
English (en)
Korean (ko)
Inventor
아만다 아타나시오
게리 헤르만
메간 피. 오브라이언
제이미 엠. 오렝고
로라 페를리
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Publication of KR20230030573A publication Critical patent/KR20230030573A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
KR1020227043651A 2020-07-01 2021-06-30 항-bet v1 항체를 사용하여 알러지를 치료하는 방법 Pending KR20230030573A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063047126P 2020-07-01 2020-07-01
US63/047,126 2020-07-01
US202063129253P 2020-12-22 2020-12-22
US63/129,253 2020-12-22
PCT/US2021/039945 WO2022006305A1 (en) 2020-07-01 2021-06-30 Methods of treating allergy using anti-bet v 1 antibodies

Publications (1)

Publication Number Publication Date
KR20230030573A true KR20230030573A (ko) 2023-03-06

Family

ID=77168400

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227043651A Pending KR20230030573A (ko) 2020-07-01 2021-06-30 항-bet v1 항체를 사용하여 알러지를 치료하는 방법

Country Status (12)

Country Link
US (2) US11897945B2 (https=)
EP (1) EP4175986A1 (https=)
JP (1) JP2023531968A (https=)
KR (1) KR20230030573A (https=)
CN (1) CN115698059A (https=)
AU (1) AU2021300129A1 (https=)
BR (1) BR112022026279A2 (https=)
CA (1) CA3177918A1 (https=)
CL (1) CL2022003744A1 (https=)
IL (1) IL299207A (https=)
MX (1) MX2022015677A (https=)
WO (1) WO2022006305A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298034B2 (en) * 2017-06-01 2024-05-01 Regeneron Pharma Antibodies against BET V 1 and methods of using them
CA3177918A1 (en) 2020-07-01 2022-01-06 Amanda ATANASIO Methods of treating allergy using anti-bet v 1 antibodies
WO2024251358A1 (en) * 2023-06-07 2024-12-12 Mabylon Ag Anti-allergen antibodies and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010194A2 (de) 1992-10-27 1994-05-11 Biomay Produktions- Und Handelsgesellschaft M.B.H. MOLEKÜLFRAGMENTE (PEPTIDE) DER HAUPTALLERGENE DER POLLEN VON BÄUMEN DER ORDNUNG $i(FAGALES)
WO1994014475A1 (en) 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
EP0619323A1 (en) 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1219299T4 (da) 2000-12-28 2011-02-14 Biomay Ag Allergivacciner og fremstilling deraf
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
ITMI20052517A1 (it) 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
AT503297B1 (de) 2006-05-18 2007-09-15 Biomay Ag Allergen-spezifische antikörper
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US10935554B2 (en) 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
IL298034B2 (en) 2017-06-01 2024-05-01 Regeneron Pharma Antibodies against BET V 1 and methods of using them
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
CA3177918A1 (en) 2020-07-01 2022-01-06 Amanda ATANASIO Methods of treating allergy using anti-bet v 1 antibodies
US20250263471A1 (en) 2024-01-30 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies

Also Published As

Publication number Publication date
CL2022003744A1 (es) 2023-06-02
JP2023531968A (ja) 2023-07-26
US20240209074A1 (en) 2024-06-27
US12583914B2 (en) 2026-03-24
IL299207A (en) 2023-02-01
AU2021300129A1 (en) 2022-12-08
MX2022015677A (es) 2023-02-22
CA3177918A1 (en) 2022-01-06
EP4175986A1 (en) 2023-05-10
WO2022006305A1 (en) 2022-01-06
BR112022026279A2 (pt) 2023-02-14
US20220002394A1 (en) 2022-01-06
CN115698059A (zh) 2023-02-03
US11897945B2 (en) 2024-02-13

Similar Documents

Publication Publication Date Title
JP7061163B2 (ja) Ｉｌ－４ｒ阻害剤の投与によるアレルギー処置方法およびアレルゲン特異的免疫療法の向上方法
US20240350625A1 (en) Combination of il-4/il-13 pathway inhibitors and plasma cell abalation for treating allergy
JP7458453B2 (ja) Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法
US11504426B2 (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
US20220220211A1 (en) Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
US12583914B2 (en) Methods of treating allergy using anti-bet v 1 antibodies
US20250263471A1 (en) Methods of treating allergy using anti-bet v 1 antibodies
US20240092882A1 (en) Method of treating an allergy with allergen-specific monoclonal antibodies
RU2833729C2 (ru) Способы лечения аллергии и усиления аллерген-специфической иммунотерапии путем введения антагониста il-4r
EA049619B1 (ru) Способы лечения аллергии с применением антител к bet v 1
WO2022089595A1 (en) Biomarkers for ige-mediated diseases
CN116887858A (zh) 通过施用il-4r拮抗剂治疗花生过敏并增强花生过敏原特异性免疫疗法的方法
RU2777328C2 (ru) Способы предупреждения или лечения аллергии посредством введения антагониста il-4r

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221213

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240610

Comment text: Request for Examination of Application